GU Cancers 2025 | 2025 updates of the DAD-IO trial in treatment-naïve urothelial carcinoma
The Phase I DAD trial (NCT04724018) initially demonstrated promising response rates in patients with treatment-naïve metastatic urothelial carcinoma receiving sacituzumab govitecan with enfortumab vedotin. Bradley McGregor, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the DAD-IO trial, an extension of the aforementioned trial, which will assess sacituzumab govitecan, enfortumab vedotin, and pembrolizumab in the first line setting. Due to toxicity concerns, doses of sacituzumab govitecan will be lower than that given in the TROPiCS-04 trial (NCT04527991). This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
